We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+30.58%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.89B
AUM Growth
+$619M
Cap. Flow
+$427M
Cap. Flow %
14.76%
Top 10 Hldgs %
55.7%
Holding
79
New
14
Increased
13
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$117M
2
PMVP icon
PMV Pharmaceuticals
PMVP
+$83.5M
3
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$52.2M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$48.2M
5
RLAY icon
Relay Therapeutics
RLAY
+$47.7M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$107M
2
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$36.3M
3
TRIL
Trillium Therapeutics Inc.
TRIL
+$33M
4
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$6.45M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.49M

Sector Composition

Rank Sector Weight
1 Healthcare 85.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLMD icon
51
Relmada Therapeutics
RLMD
$557M
$11.3M 0.39%
300,000
– –
PSTX
52
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$11.1M 0.38%
+1,251,055
New +$14.2M
MREO
53
Mereo BioPharma
MREO
$54.7M
$10.6M 0.36%
4,029,649
– –
LITS
54
Lite Strategy Inc
LITS
$32.8M
$9.09M 0.31%
145,655
– –
NUVB icon
55
Nuvation Bio
NUVB
$2.2B
$8.96M 0.31%
+800,000
New +$8.64M
MTNB icon
56
Matinas BioPharma
MTNB
$1.88M
$8.79M 0.3%
229,573
– –
RNAC icon
57
Cartesian Therapeutics
RNAC
$229M
$8.14M 0.28%
109,469
– –
FSDC
58
DELISTED
FS Development Corp. Class A Common Stock
FSDC
$7.84M 0.27%
+700,000
New +$7.49M
ZYME icon
59
Zymeworks
ZYME
$1.61B
$7.69M 0.27%
165,000
– –
ARVN icon
60
Arvinas
ARVN
$518M
$7.08M 0.24%
+300,000
New +$8.69M
BLU
61
DELISTED
BELLUS Health Inc.
BLU
$6.75M 0.23%
2,975,000
+1,200,000
+68% +$3.4M
XENE icon
62
Xenon Pharmaceuticals
XENE
$6.06B
$6.64M 0.23%
600,000
– –
NAUT icon
63
Nautilus Biotechnolgy
NAUT
$124M
$6.27M 0.22%
+600,000
New +$6.4M
MIRM icon
64
Mirum Pharmaceuticals
MIRM
$6.46B
$6.11M 0.21%
317,000
– –
FULC icon
65
Fulcrum Therapeutics
FULC
$239M
$5.6M 0.19%
705,882
– –
KNSA icon
66
Kiniksa Pharmaceuticals
KNSA
$5.8B
$4.45M 0.15%
290,577
– –
OBIO icon
67
Orchestra BioMed
OBIO
$238M
$4.4M 0.15%
+400,000
New +$4.49M
LSACU
68
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
$4.08M 0.14%
300,000
– –
SYRE icon
69
Spyre Therapeutics
SYRE
$8.54B
$3.9M 0.13%
22,000
– –
LJPC
70
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.59M 0.12%
890,700
– –
TARA icon
71
Protara Therapeutics
TARA
$220M
$3.52M 0.12%
209,227
– –
SLDB icon
72
Solid Biosciences
SLDB
$794M
$3.11M 0.11%
102,125
– –
GNCA
73
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.6M 0.09%
+1,134,453
New +$2.98M
CLRB icon
74
Cellectar Biosciences
CLRB
$20.5M
$1.14M 0.04%
3,067
– –
ZGNX
75
DELISTED
Zogenix, Inc.
ZGNX
$489K 0.02%
27,300
– –
1 2
3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Boxer Capital held 79 positions worth $2.89B, up 27% from $2.27B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Boxer Capital deployed $427M of net new capital in Q3 2020, opening 14 new positions and adding to 13 existing holdings. Its largest new stake was iTeos Therapeutics: 4,345,016 shares worth $107M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 86% a quarter earlier.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $107M trimmed.

  • Boxer Capital's largest Q3 2020 buy was iTeos Therapeutics: 4,345,016 shares worth $107M.
  • Boxer Capital added most to Odonate Therapeutics, Inc. Common Stock in Q3 2020, an estimated $52.2M increase.
  • Boxer Capital's biggest Q3 2020 reduction was Immunomedics Inc, cutting an estimated $107M.
  • Boxer Capital fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $36.3M.
  • Boxer Capital's ten largest holdings make up 56% of its $2.89B portfolio in Q3 2020.
  • Boxer Capital opened 14 new positions and closed 4 in Q3 2020.
  • Boxer Capital's portfolio value rose 27% quarter-over-quarter to $2.89B.

Based on Boxer Capital's 13F filing for Q3 2020, filed 16 Nov 2020.